Cointime

Thrive Earlier Detection

company

About

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

  • 101 - 250

Highlights

Total Funding Amount
$257M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$257M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical
Founded date
May 30, 2019
Number Of Employee
101 - 250
Operating Status
Active

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care.

It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.

The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$257M
Thrive Earlier Detection has raised a total of $257M in funding over 2 rounds. Their latest funding was raised on Jul 29, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 29, 2020 Series B $257M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Thrive Earlier Detection is funded by 1 investors. Exact Sciences are the most recent investors.
Investor Name Lead Investor Funding Round
Exact Sciences — Series B
Cointime
เนื้อหา
บริษัท